Johnson & Johnson (JNJ)

123.99
0.25 0.20
NYSE : Health Technology
Prev Close 124.24
Open 124.74
Day Low/High 124.03 / 124.99
52 Wk Low/High 121.28 / 148.32
Volume 2.58M
Avg Volume 6.57M
Exchange NYSE
Shares Outstanding 2.68B
Market Cap 335.62B
EPS 0.50
P/E Ratio 269.24
Div & Yield 3.60 (2.68%)

Latest News

Stocks With Great Pin Action: Cramer's 'Mad Money' Recap (Wednesday 5/16/18)

Stocks With Great Pin Action: Cramer's 'Mad Money' Recap (Wednesday 5/16/18)

Jim Cramer says it's possible for just a few stocks to drive the market higher -- if they are important to their sectors and have good pin action.

On JPMorgan's Board, Women Are Fewer Than a Few

On JPMorgan's Board, Women Are Fewer Than a Few

JPMorgan CEO Jamie Dimon has a much-vaunted track record of promoting women to senior roles on his executive team. But the number of women on the U.S. bank's board of directors has stalled out at two since 2006, despite research showing greater female representation improves long-term returns.

2 Trading Opportunities in Health Care

2 Trading Opportunities in Health Care

The potential of these setups on the weekly chart is rather good.

The New #10 Most Shorted Dow Component: Johnson & Johnson

The most recent short interest data has been released for the 04/30/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

CVS Health, Prestige Brands, LendingTree: 'Mad Money' Lightning Round

CVS Health, Prestige Brands, LendingTree: 'Mad Money' Lightning Round

Jim Cramer takes a look at CVS Health, Prestige Brands, LendingTree, Valeant Pharmaceuticals, Nektar Therapeutics, Kirkland Lake and more.

Buffett's Optimism Rules: Cramer's 'Mad Money' Recap (Monday 5/7/18)

Buffett's Optimism Rules: Cramer's 'Mad Money' Recap (Monday 5/7/18)

Jim Cramer says Warren Buffett is the greatest investor, and his optimism has suffused trading and has been justified.

Checked the 52-Week Low List Lately? It's a Graveyard of Well-Known Stocks

Checked the 52-Week Low List Lately? It's a Graveyard of Well-Known Stocks

What's really surprising is the emergence of so many household names on the list.

New Phase 3 Data Show Esketamine Nasal Spray Demonstrated Rapid Improvements In Depressive Symptoms In Patients With Treatment-Resistant Depression

- Study in adults with treatment-resistant depression marks the first time an antidepressant has achieved superiority in a clinical trial for major depressive disorder that included a newly initiated oral antidepressant in both the control and placebo groups

What to Expect From Allergan, Aetna, Merck and Pfizer's Earnings Next Week

What to Expect From Allergan, Aetna, Merck and Pfizer's Earnings Next Week

The drugmakers and health insurer are preparing to unveil first-quarter numbers.

Daily Chatter: Trillion Dollar Babies

Daily Chatter: Trillion Dollar Babies

A solid set of earnings from the world's biggest tech companies has global stocks on the march again Friday, while the U.S. dollar tests 2018 highs as the world's biggest economy continues to expand.

Fate of Pfizer Unit in Spotlight After Merck Sells Consumer Business

Fate of Pfizer Unit in Spotlight After Merck Sells Consumer Business

Procter & Gamble, which is buying the Merck unit, was previously reported to be in talks to acquire Pfizer's consumer healthcare business.

P&G, GE and IBM Need to Innovate; Has Starbucks' Stock Grown Ice Cold?--ICYMI

P&G, GE and IBM Need to Innovate; Has Starbucks' Stock Grown Ice Cold?--ICYMI

Here's what you need to know now for Thursday, April 19.

Jim Cramer: Reports of FANG's Death Greatly Exaggerated

Jim Cramer: Reports of FANG's Death Greatly Exaggerated

The big story is about cloud adoption.

Dow Jumps Over 200 Points; S&P 500 and Nasdaq Also Finish Higher

Dow Jumps Over 200 Points; S&P 500 and Nasdaq Also Finish Higher

Stocks rise on Tuesday as investors react to strong earnings from Goldman Sachs and Netflix.

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer and our other experts discuss Netflix and the FANGS, stock picking rewarded, and a way to hide from political risk.

Goldman Sachs, Netflix, Tesla - 5 Things You Must Know Before the Market Opens

Goldman Sachs, Netflix, Tesla - 5 Things You Must Know Before the Market Opens

U.S. stock futures point to gains for Wall Street on Tuesday; Goldman Sachs, UnitedHealth and Johnson & Johnson report earnings; Netflix surges after it posts impressive subscriber growth; Tesla to temporarily suspend production of Model 3 sedan.

Wall Street Looks To Extends Gains After Goldman Earnings Beat, China Data

Wall Street Looks To Extends Gains After Goldman Earnings Beat, China Data

Global stocks bumped higher Tuesday, while Wall Street futures suggested another positive open, as investors digested a mix set of economic readings from China and continued to focus on the U.S. corporate earnings season.

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Spotify, Alkermes, Sorrento Therapeutics: 'Mad Money' Lightning Round

Jim Cramer highlights Spotify, Alkermes, Sorrento Therapeutics, Thermo Fisher Scientific, Kohlberg Kravis Roberts, and more.

Unreasonable Earnings Expectations?: Cramer's 'Mad Money' Recap (Monday 4/16/18)

Unreasonable Earnings Expectations?: Cramer's 'Mad Money' Recap (Monday 4/16/18)

Washington receded and earnings came to the fore, but we're still seeing insane values and some surprises, says Jim Cramer.

Dow Jumps 212 Points as Wall Street Shrugs Off Syria and Turns to Earnings

Dow Jumps 212 Points as Wall Street Shrugs Off Syria and Turns to Earnings

Stocks rise Monday as concerns over prolonged military action in Syria fade and the focus for investors shifts to a heavy upcoming slate of U.S. corporate earnings.

Global Stocks Mixed, Wall Street Steady as Syria Strikes Keep Investors on Edge

Global Stocks Mixed, Wall Street Steady as Syria Strikes Keep Investors on Edge

U.S. equity futures gave back earlier gains Monday even as investor concern over prolonged military action in Syria faded following weekend missile strikes in reaction to an alleged chemicals weapons attack last week in the city of Douma.

Syria, James Comey, Bank of America, WPP and Starbucks - 5 Things You Must Know

Syria, James Comey, Bank of America, WPP and Starbucks - 5 Things You Must Know

U.S. stock futures are rising Monday as concerns over prolonged military action in Syria fade; Bank of America and Netflix report earnings on Monday; Former FBI Director James Comey says Donald Trump 'morally unfit' to be president; WPP CEO Martin Sorrell quits.

Washington Woes Slam Stocks: Cramer's 'Mad Money' Recap (Friday 4/13/18)

Washington Woes Slam Stocks: Cramer's 'Mad Money' Recap (Friday 4/13/18)

President Trump is creating a level of uncertainty that breeds selling. But Jim Cramer has your game plan for next week.

Week in Review: Wall Street Cowers in Washington's Shadow, Leaving Markets Mixed

Week in Review: Wall Street Cowers in Washington's Shadow, Leaving Markets Mixed

Markets have been mixed throughout the week, again extra sensitive to the fragile trade relationship between the U.S. and China. Plus, earnings season gets going and Facebook faces the music.

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

U.S. Senator Cory Booker Criticizes Pharma Companies in New Tax Report

The Trump Administration cut corporate taxes and U.S. Senator Cory Booker hoped pharma companies would cut drug prices. That didn't happen and Booker's new analysis hammers those drug companies.

TheStreet Quant Rating: C+ (Hold)